PRO-CEFUROXIME - 500 TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
23-09-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CEFUROXIME (CEFUROXIME AXETIL)
Fáanlegur frá:
PRO DOC LIMITEE
ATC númer:
J01DC02
INN (Alþjóðlegt nafn):
CEFUROXIME
Skammtar:
500MG
Lyfjaform:
TABLET
Samsetning:
CEFUROXIME (CEFUROXIME AXETIL) 500MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
SECOND GENERATION CEPHALOSPORINS
Vörulýsing:
Active ingredient group (AIG) number: 0122448002; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2021-05-31
Vara einkenni
Page 1 of 27
PRODUCT MONOGRAPH
PR
PRO-CEFUROXIME - 500
CEFUROXIME AXETIL TABLETS, USP
500 MG CEFUROXIME / TABLET
ANTIBIOTIC
PRO DOC LTÉE
DATE OF REVISION:
2925, boul. Industriel
September 23, 2019
Laval, Quebec
H7L 3W9
CONTROL NO.: 229806
Page 2 of 27
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
......................................................................................................
6
DRUG INTERACTIONS
.......................................................................................................
7
DOSAGE AND ADMINISTRATION
......................................................................................
8
OVERDOSAGE
....................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
9
STORAGE AND
STABILITY.................................................................................................
9
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 9
PART II: SCIENTIFIC INFORMATION
....................................................................................10
PHARMACEUTICAL INFORMATION
..................................................................................10
CLINICAL TRIALS
...............................................................................................................11
DETAILED PHARMACOLOGY
....
Lestu allt skjalið
